Amgen Biosimilars Study Predicts Significant Advances
Company Has Invested Over $2bn In Its Portfolio Of 10 Biosimilars
Executive Summary
Amgen’s 2021 Biosimilars Trends Report predicts several imminent advancements in the biosimilars space, especially with the expected US launches of biosimilars to Humira in 2023. According to Amgen, the marketplace is poised to see further growth.